/Regeneron%20Pharmaceuticals%2C%20Inc_%20pharmaceuticals%20by-%20okskaz%20via%20iStock.jpg)
With a market cap of $62.4 billion, Regeneron Pharmaceuticals, Inc. (REGN) discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. Based in Tarrytown, New York, the company’s products include EYLEA, Dupixent, Libtayo, Praluent, REGEN-COV, and Kevzara.
The company is expected to report its Q1 earnings on Tuesday, Apr. 29, before the market opens. Ahead of the event, analysts expect REGN to report an EPS of $7 per share, down 12.2% from $7.97 per share reported in the year-ago quarter. It has exceeded analysts' earnings estimates in three of the past four quarters, while only missing in one occassion. Its EPS of $9.90 in the recent quarter surpassed analysts’ expectations by 2.9%, driven by higher sales of its Dupixent, EYLEA HD and EYLEA, and Libtayo.